195 related articles for article (PubMed ID: 27216304)
1. A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.
Miller ML; Fishkin NE; Li W; Whiteman KR; Kovtun Y; Reid EE; Archer KE; Maloney EK; Audette CA; Mayo MF; Wilhelm A; Modafferi HA; Singh R; Pinkas J; Goldmacher V; Lambert JM; Chari RV
Mol Cancer Ther; 2016 Aug; 15(8):1870-8. PubMed ID: 27216304
[TBL] [Abstract][Full Text] [Related]
2. A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).
Miller ML; Shizuka M; Wilhelm A; Salomon P; Reid EE; Lanieri L; Sikka S; Maloney EK; Harvey L; Qiu Q; Archer KE; Bai C; Vitharana D; Harris L; Singh R; Ponte JF; Yoder NC; Kovtun Y; Lai KC; Ab O; Pinkas J; Keating TA; Chari RVJ
Mol Cancer Ther; 2018 Mar; 17(3):650-660. PubMed ID: 29440292
[TBL] [Abstract][Full Text] [Related]
3. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs).
Reid EE; Archer KE; Shizuka M; McShea MA; Maloney EK; Ab O; Lanieri L; Wilhelm A; Ponte JF; Yoder NC; Chari RVJ; Miller ML
Bioorg Med Chem Lett; 2019 Sep; 29(17):2455-2458. PubMed ID: 31350125
[TBL] [Abstract][Full Text] [Related]
5. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
6. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.
Kumar A; Kinneer K; Masterson L; Ezeadi E; Howard P; Wu H; Gao C; Dimasi N
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3617-3621. PubMed ID: 30389292
[TBL] [Abstract][Full Text] [Related]
8. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
[TBL] [Abstract][Full Text] [Related]
9. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence.
Gong X; Azhdarinia A; Ghosh SC; Xiong W; An Z; Liu Q; Carmon KS
Mol Cancer Ther; 2016 Jul; 15(7):1580-90. PubMed ID: 27207778
[TBL] [Abstract][Full Text] [Related]
10. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models.
Tsumura R; Manabe S; Takashima H; Koga Y; Yasunaga M; Matsumura Y
Cancer Sci; 2019 Oct; 110(10):3296-3305. PubMed ID: 31348600
[TBL] [Abstract][Full Text] [Related]
12. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC
Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920
[TBL] [Abstract][Full Text] [Related]
13. Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates.
Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Tang S; Protopopova M; Kelleher E; Jones B; Yang L; Custar D; Catcott KC; Demady DR; Collins SD; Xu L; Bu C; Qin L; Ter-Ovanesyan E; Damelin M; Toader D; Lowinger TB
Mol Cancer Ther; 2024 Apr; 23(4):541-551. PubMed ID: 38354416
[TBL] [Abstract][Full Text] [Related]
14. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
15. Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves
Nessler I; Khera E; Vance S; Kopp A; Qiu Q; Keating TA; Abu-Yousif AO; Sandal T; Legg J; Thompson L; Goodwin N; Thurber GM
Cancer Res; 2020 Mar; 80(6):1268-1278. PubMed ID: 31941698
[TBL] [Abstract][Full Text] [Related]
16. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
17. Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect.
Nicolaou KC; Rigol S; Pitsinos EN; Das D; Lu Y; Rout S; Schammel AW; Holte D; Lin B; Gu C; Sarvaiya H; Trinidad J; Barbour N; Valdiosera AM; Sandoval J; Lee C; Aujay M; Fernando H; Dhar A; Karsunky H; Taylor N; Pysz M; Gavrilyuk J
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34155147
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD
J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.
Zhang D; Yu SF; Khojasteh SC; Ma Y; Pillow TH; Sadowsky JD; Su D; Kozak KR; Xu K; Polson AG; Dragovich PS; Hop CECA
Mol Cancer Ther; 2018 Mar; 17(3):677-685. PubMed ID: 29348271
[TBL] [Abstract][Full Text] [Related]
20. Contribution of linker stability to the activities of anticancer immunoconjugates.
Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
